RE:Ya good read from the website ...Gobbs, we already knew what the cash position was at the end of March. So nothing newsworthy there.
What is interesting for me is the the apparent change of strategy for the roll out of Ryplazim. In the Q1 MDA and the annual security exchange filings, it is made clear that the company would not explore further applications of Ryplazim or any other plasma protein for that matter. Now the company is talking about looking into other acute applications as well as wound healing. It also introduces the possibility of the marketing of Ryplazim in the USA being undertaken by ‘us’ or through a collaboration.
What has happened in the last couple of weeks that would lead to such a dramatic change of strategy, especially since the company is strapped for cash? Could be all BS to make the company more attractive especially if it needs to do an equity raise in the market. Or is it something else? The intrigue will at least make the annual meeting a bit more interesting or not???